Literature DB >> 8094546

Inflammatory cells in proliferative vitreoretinopathy subretinal membranes.

D G Charteris1, P Hiscott, H L Robey, Z J Gregor, S L Lightman, I Grierson.   

Abstract

BACKGROUND: The inflammatory cell content of subretinal membranes occurring in proliferative vitreoretinopathy (PVR) has not yet been well characterized. This study was undertaken to investigate the inflammatory cells present in PVR subretinal membranes.
METHODS: Eight subretinal membranes obtained surgically from eyes with PVR complicating rhegmatogenous retinal detachment were studied immunohistochemically using the avidin-biotin complex technique and a panel of monoclonal and polyclonal antibodies.
RESULTS: T lymphocytes were found in five of the eight subretinal membranes. CD4+ T cells were demonstrated in four and CD8+ T cells in one of the membranes. T cells bearing the interleukin 2 receptor were found in two of four membranes studied. Macrophages were found in four membranes. No B lymphocytes or neutrophils were demonstrated, and there were no significant deposits of complement or immunoglobulins. Expression of the MHC class II antigen HLA DR was consistently found in frozen specimens. Glial cells and retinal pigment epithelial cells also were present in the membranes, often adjacent to T cells, although overall no obvious relationship was found between glial or retinal epithelial cells and T cells.
CONCLUSION: The findings indicate that T lymphocytes are present in PVR subretinal membranes and have the potential to interact with other cell types in the pathogenesis of this condition.

Entities:  

Mesh:

Year:  1993        PMID: 8094546     DOI: 10.1016/s0161-6420(93)31711-2

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  17 in total

1.  Immunopathology of intraocular silicone oil: retina and epiretinal membranes.

Authors:  Louisa J Wickham; Riaz H Asaria; Robert Alexander; Phil Luthert; David G Charteris
Journal:  Br J Ophthalmol       Date:  2006-09-27       Impact factor: 4.638

2.  Vitreous body affects activation and maturation of monocytes into macrophages.

Authors:  R Osuský; S M Walker; S J Ryan
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1996-10       Impact factor: 3.117

Review 3.  Proliferative vitreoretinopathy: pathobiology, surgical management, and adjunctive treatment.

Authors:  D G Charteris
Journal:  Br J Ophthalmol       Date:  1995-10       Impact factor: 4.638

4.  Induction of interleukin-8 in human retinal pigment epithelial cells after denuding injury.

Authors:  A Yoshida; S G Elner; Z M Bian; V M Elner
Journal:  Br J Ophthalmol       Date:  2001-07       Impact factor: 4.638

5.  Retinal MMP-12, MMP-13, TIMP-1, and TIMP-2 expression in murine experimental retinal detachment.

Authors:  Bongsu Kim; Mohamed H Abdel-Rahman; Tiffany Wang; Severin Pouly; Ashraf M Mahmoud; Colleen M Cebulla
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-04-03       Impact factor: 4.799

6.  The effect of a preoperative subconjuntival injection of dexamethasone on blood-retinal barrier breakdown following scleral buckling retinal detachment surgery: a prospective randomized placebo-controlled double blind clinical trial.

Authors:  Ernesto Bali; Eric J Feron; Ed Peperkamp; Marc Veckeneer; Paul G Mulder; Jan C van Meurs
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-02-25       Impact factor: 3.117

Review 7.  Advances in the use of prodrugs for drug delivery to the eye.

Authors:  Pranjal Taskar; Akshaya Tatke; Soumyajit Majumdar
Journal:  Expert Opin Drug Deliv       Date:  2016-07-21       Impact factor: 6.648

8.  Application of sustained delivery microsphere of cyclosporine A for preventing posterior capsular opacification in rabbits.

Authors:  Cheng Pei; Yi Xu; Jean Xin Jiang; Li-Jun Cui; Li Li; Li Qin
Journal:  Int J Ophthalmol       Date:  2013-02-18       Impact factor: 1.779

9.  Interleukin and growth factor levels in subretinal fluid in rhegmatogenous retinal detachment: a case-control study.

Authors:  Lukas J A G Ricker; Aize Kijlstra; Alfons G H Kessels; Wilco de Jager; Albert T A Liem; Fred Hendrikse; Ellen C La Heij
Journal:  PLoS One       Date:  2011-04-27       Impact factor: 3.240

10.  Adalimumab (tumor necrosis factor-blocker) reduces the expression of glial fibrillary acidic protein immunoreactivity increased by exogenous tumor necrosis factor alpha in an organotypic culture of porcine neuroretina.

Authors:  I Fernandez-Bueno; M T Garcia-Gutierrez; G K Srivastava; M J Gayoso; J M Gonzalo-Orden; J C Pastor
Journal:  Mol Vis       Date:  2013-04-17       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.